Skip to main content

Advertisement

SpringerLink
Log in

The Androgen Receptor: Is It a Promising Target?

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

A growing body of literature supports the conclusion that the androgen receptor (AR) plays an important role in breast cancer pathogenesis and may prove to be a relevant therapeutic target for patients with AR-driven breast cancer. This has been most apparent in the subset of patients with triple-negative breast cancer (TNBC), in whom approximately 50% of tumors may have androgen dependence. Recent phase 2 clinical trials of agents that antagonize AR or reduce androgen production have shown clinical benefit and efficacy to varying degrees. This review highlights three of these recent trials of AR+ TNBC and acknowledge ongoing research in this exciting area.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.

    Article  CAS  PubMed  Google Scholar 

  2. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100: 8418–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003;100:10393–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005;24:4660–71.

    Article  CAS  PubMed  Google Scholar 

  5. Doane AS, Danso M, Lal P, et al. An estrogen-receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 2006;25:3994–4008.

    Article  CAS  PubMed  Google Scholar 

  6. Cochrane DR, Bernales S, Jacobsen BM, et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014;16:R7.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Gucalp A, Tolaney S, Isakoff SJ, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen-receptor-negative metastatic breast cancer. Clin Cancer Res. 2013;19:5505–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Bonnefoi H, Grellety T, Tredan O, et al. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor-positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann Oncol. 2016;27:812–18.

    Article  CAS  PubMed  Google Scholar 

  9. Traina TA, Miller K, Yardley DA, et al. Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). ASCO Meeting Abstracts. 2015;33:1003.

    Google Scholar 

  10. Perrault DJ, Logan DM, Stewart DJ, et al. Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. Invest New Drugs. 1988;6:207–10.

    Article  CAS  PubMed  Google Scholar 

  11. Shore ND, Chowdhury S, Villers A, et al. (2016) Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 17:153–163.

    Article  CAS  PubMed  Google Scholar 

  12. Penson DF, Armstrong AJ, Concepcion R, et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: The STRIVE Trial. J Clin Oncol. 2016;34:2098–106.

    Article  CAS  PubMed  Google Scholar 

  13. Elias A, Burris H, Patel M, et al. Abstract P1-16-05: MDV3100-08: a phase 1 study evaluating the safety and pharmacokinetics of enzalutamide plus fulvestrant in women with advanced hormone receptor-positive breast cancer. Cancer Res. 2016;76:P1–P16.

    Article  Google Scholar 

  14. Traina T, Yardley D, Patel M, et al. Abstract PD3-6: a phase 1 open-label, dose-escalation study evaluating the safety, tolerability, and pharmacokinetics of enzalutamide (previously MDV3100) alone or in combination with an aromatase inhibitor in women with advanced breast cancer. Cancer Res. 2013;73:PD3–PD6.

    Google Scholar 

  15. Parker JS, Peterson AC, Tudor IC, et al. A novel biomarker to predict sensitivity to enzalutamide (ENZA) in TNBC. J Clin Oncol. 2015;33:1083.

    Article  Google Scholar 

  16. Bardia A, Dacosta NA, Gabrail NY, et al. Phase (Ph) 1 study of oral seviteronel (VT-464), a dual CYP17-Lyase (L) inhibitor and androgen receptor (AR) antagonist, in patients (pts) with advanced AR+ triple-negative (TNBC) or estrogen receptor (ER)+ breast cancer (BC). ASCO Meeting Abstracts. 2016;34:1088.

    Google Scholar 

  17. Finn RS, Martin M, Rugo HS, et al. PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2− advanced breast cancer (ABC). ASCO Meeting Abstracts. 2016;34:507.

    Google Scholar 

  18. Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor–positive advanced breast cancer. N Engl J Med. 2015;373:209–19.

    Article  CAS  PubMed  Google Scholar 

  19. Cadoo KA, Gucalp A, Traina TA (2014) Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. Breast Cancer Targets Ther 6:123.

    CAS  Google Scholar 

  20. Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen-receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11:R77.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Gucalp A, Proverbs-Singh TA, Corben A, et al. Phase I/II trial of palbociclib in combination with bicalutamide for the treatment of androgen receptor (AR)+ metastatic breast cancer (MBC). ASCO Meeting Abstracts. 2016;34:TPS1103.

  22. Doane AS MM, Zhang L, Hudis C, Gerald WL (2006) PIK3CA mutation is frequent in class A estrogen-receptor-negative breast cancer and contributes to the distinct molecular profile. Breast Cancer Res Treat. 100:S293.

    Article  Google Scholar 

  23. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res. 2009;15:2472–78.

    Article  CAS  PubMed  Google Scholar 

  24. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Aleskandarany MA, Rakha EA, Ahmed MA et al. Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer. Breast Cancer Res Treat. 2011;127:407–16.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosures

Authors receive research funding from Innocrin, Pfizer/Medivation and Astellas. Dr. Traina has honoraria from consulting for Innocrin, Pfizer and Astellas. Dr. Gucalp has honoraria from consulting for Pfizer.

Author information

Authors and Affiliations

  1. Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Ayca Gucalp MD & Tiffany A. Traina MD

  2. Evelyn H. Lauder Breast Center, Weill Cornell Medical College, New York, NY, USA

    Ayca Gucalp MD & Tiffany A. Traina MD

Authors
  1. Ayca Gucalp MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tiffany A. Traina MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tiffany A. Traina MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gucalp, A., Traina, T.A. The Androgen Receptor: Is It a Promising Target?. Ann Surg Oncol 24, 2876–2880 (2017). https://doi.org/10.1245/s10434-017-5961-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-017-5961-9

Keywords

Search

Navigation